Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.
about
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in CancerGlycomic Approaches for the Discovery of Targets in Gastrointestinal CancerThe Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer ProgressionDysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic AgentsPotential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsAdvancement of Sialyltransferase Inhibitors: Therapeutic Challenges and OpportunitiesAdhesion GPCRs in Tumorigenesis.A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies.Antibody repertoire profiling with mimotope arrays.Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in SerumPrecision glycocalyx editing as a strategy for cancer immunotherapy.Sialic acids in cancer biology and immunity.The immune system and cancer evasion strategies: therapeutic concepts.Chemical Synthesis and Evaluation of a Disialic Acid-Containing Dextran Polymer as an Inhibitor for the Interaction between Siglec 7 and Its Ligand.Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update.Carcinoma-associated fucosylated antigens are markers of the epithelial state and can contribute to cell adhesion through CLEC17A (Prolectin).Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.SAMP-ending down sepsis.Selectins in cancer immunity.A Developed NK-92MI Cell Line with Siglec-7neg Phenotype Exhibits High and Sustainable Cytotoxicity against Leukemia Cells.A Cartography of Siglecs and Sialyltransferases in Gynecologic Malignancies: Is There a Road Towards a Sweet Future?Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.
P2860
Q26744538-73216982-62BB-4B69-BC65-3B99CFFD96A7Q26750872-E9412CD0-A284-4412-98D8-0CA862891D5DQ26750877-98DD72C6-9775-4C17-A448-DE1D5D57962DQ26771367-0594CA96-4C7D-46AC-89CD-7CB57B935449Q26775033-37598BA3-3D4F-45F0-B5C0-44599DE723BDQ30039640-14261DFF-BD3E-4A6A-B964-8E60489EE279Q33558191-CB96C47C-E637-4B50-B5B7-B66F32D06C1CQ34484061-D082E3C9-3A80-48CF-8C71-A978FDE65A5DQ36215753-91CE60D9-6674-4CEE-9130-5F598F8F3E19Q36451478-0EFEE81A-540C-4936-841A-3A8C06928011Q37264064-832F6C01-37C6-4731-BA6B-C34C924A9868Q38620799-462E0394-EB39-4FE9-85AE-B3D640AB02B6Q38691172-BEB42394-A3CC-4810-B512-5BFD1B61A2A9Q38856537-F09CA292-F5FC-4363-8B09-819D6D644C99Q38928047-06A114B0-040F-422A-8822-F47E577F5774Q39974354-84B73A20-25E7-4E7E-B4C7-09891C37E950Q40729252-81ED13F8-3FE0-4677-B750-CBC75FC8739AQ42330827-D332DF8E-AEB9-4256-B9AD-81CAC69BDBC7Q49617012-97DED2A4-263C-4138-9236-CC29DF342F22Q52607627-3BDE0B28-AA08-41A9-AFBD-0886987D609FQ55402574-BF490977-F4D4-47D6-9E9F-D765ACC0CF48Q55515607-2DEA017E-6C9B-40DE-82C8-403A3CD99DF6
P2860
Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Cancer intelligence acquired ( ...... dismantling antitumor defense.
@en
type
label
Cancer intelligence acquired ( ...... dismantling antitumor defense.
@en
prefLabel
Cancer intelligence acquired ( ...... dismantling antitumor defense.
@en
P2093
P2860
P1476
Cancer intelligence acquired ( ...... dismantling antitumor defense.
@en
P2093
Circe Mesa
Kayluz Frias Boligan
Luis Enrique Fernandez
P2860
P2888
P304
P356
10.1007/S00018-014-1799-5
P577
2014-12-07T00:00:00Z